Acute and chronic studies of diltiazem in elderly versus young hypertensive patients
- PMID: 3687802
- DOI: 10.1016/0002-9149(87)90471-1
Acute and chronic studies of diltiazem in elderly versus young hypertensive patients
Abstract
The pharmacodynamics, disposition and hormonal responses to acute intravenous and chronic oral diltiazem treatment were compared in young and elderly hypertensive patients. In elderly patients, supine diastolic blood pressure decreased significantly during the first week of treatment (baseline mean +/- standard error of the mean, 100 +/- 1 to 93 +/- 2 mm Hg) and decreased further during the study to 86 +/- 2 mm Hg at the end of the study. Diastolic blood pressure of the young patients decreased significantly by the third week of treatment (from 104 +/- 2 to 97 +/- 3 mm Hg) and decreased further during the study to 94 +/- 2 mm Hg at the end of the study. Baseline supine systolic blood pressure was greater in elderly than in young patients (167 +/- 5 vs 144 +/- 3 mm Hg; p less than 0.01) and was significantly reduced in the elderly by the fourth week (167 +/- 5 to 154 +/- 3 mm Hg; p less than 0.003), with a significantly reduction sustained throughout the 14-week period. Young patients had little change in systolic blood pressure. Supine heart rate tended to decrease in both groups during the 14-week period. Acute intravenous diltiazem pharmacokinetics determined at the beginning of the study showed that total diltiazem clearance was similar in elderly (13.3 +/- 1.0 ml/min/kg) and young (13.7 +/- 1.9 ml/min/kg) patients as was volume of distribution (4.2 +/- 0.3 vs 4.3 +/- 0.6 liters/kg) and elimination half-life (3.78 +/- 0.19 vs 3.69 +/- 0.23 hours).(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Responses to intravenous and oral diltiazem in elderly and younger patients with systemic hypertension.Am J Cardiol. 1987 May 1;59(12):1111-7. doi: 10.1016/0002-9149(87)90858-7. Am J Cardiol. 1987. PMID: 3578052
-
Calcium antagonists in geriatric patients: diltiazem in elderly persons with hypertension.Clin Pharmacol Ther. 1989 Jun;45(6):682-91. doi: 10.1038/clpt.1989.90. Clin Pharmacol Ther. 1989. PMID: 2731407
-
Efficacy and tolerance of sustained-release diltiazem 300 mg and a diuretic in the elderly.J Cardiovasc Pharmacol. 1990;16 Suppl 1:S51-5. J Cardiovasc Pharmacol. 1990. PMID: 1706015 Clinical Trial.
-
Comparison in young and elderly patients of pharmacodynamics and disposition of labetalol in systemic hypertension.Am J Cardiol. 1987 Sep 15;60(8):697-702. doi: 10.1016/0002-9149(87)90385-7. Am J Cardiol. 1987. PMID: 3661438
-
Systolic blood pressure response in three subgroups of hypertensives treated with sustained-release diltiazem.J Cardiovasc Pharmacol. 1988;12 Suppl 6:S117-9. doi: 10.1097/00005344-198812006-00029. J Cardiovasc Pharmacol. 1988. PMID: 2468893
Cited by
-
Cardiovascular drug therapy in elderly patients: specific age-related pharmacokinetic, pharmacodynamic and therapeutic considerations.Drugs Aging. 2005;22(11):913-41. doi: 10.2165/00002512-200522110-00003. Drugs Aging. 2005. PMID: 16323970
-
Diltiazem. A reappraisal of its pharmacological properties and therapeutic use.Drugs. 1990 May;39(5):757-806. doi: 10.2165/00003495-199039050-00009. Drugs. 1990. PMID: 2191851 Review.
-
Antihypertensive therapy in the aged patient. Clinical pharmacokinetic considerations.Drugs Aging. 1991 May;1(3):194-211. doi: 10.2165/00002512-199101030-00004. Drugs Aging. 1991. PMID: 1686570 Review.
-
Diltiazem inhibits human intestinal cytochrome P450 3A (CYP3A) activity in vivo without altering the expression of intestinal mRNA or protein.Br J Clin Pharmacol. 2005 Apr;59(4):440-6. doi: 10.1111/j.1365-2125.2005.02343.x. Br J Clin Pharmacol. 2005. PMID: 15801939 Free PMC article. Clinical Trial.
-
Diltiazem. A review of its pharmacology and therapeutic use in older patients.Drugs Aging. 1993 Jul-Aug;3(4):363-90. doi: 10.2165/00002512-199303040-00007. Drugs Aging. 1993. PMID: 8369596 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical